# Novaken

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novaken

- Industry: Pharmaceuticals
- Headquarters: Guangzhou, China
- Website: www.novaken.cn
- Total disclosed funding: $16M
- Latest round: Series C (Feb 19, 2025)
- Investors on record: 4

## About

Established in 2007 and based in Guangzhou, China, Novaken operates as an innovative drug developer that focuses on the development of innovative drug formulations and technology platforms. It acquired certifications such as ISO90001, ISO14001, and ISO45001. The company has obtained more than 100 patents and high-tech enterprise certification. Dr. Chuanbin Wu, the founder of the company, used to hold senior R&D management positions in Johnson & Johnson, Novartis, and Actavis. In February 2025, Novaken closed venture funding from new investors ZJVC Venture Capital and Hengqin Financial Investment.

The company is engaged in the development of innovative drug formulations and technology platforms. It has two new drug technology platforms, which are soluble microneedles and inhalation formulations. Products include Someprazole Magnesium Enteric-coated Tablets, Nifedipine Sustained Release Tablets, Zolpidem Tartrate Sustained Release Tablets, etc. The drugs developed are suitable for eye inflammation, intestinal infection, gastrointestinal ulcers, pancreatic cancer, and other fields.

The company generates revenue by providing innovative drug formulations and technology platforms, such as Oxybunium Sustained-Release Tablets, Tacrolimus Granules, and Ribavirin Tablet.

The series C+ financing will further support the advancement of the company's R&D pipeline and the optimization of its technology platform, consolidating its leading position in the field of innovative formulations.

## Funding rounds

- Series C, Feb 19, 2025 — ZJVC Venture Capital, Hengqin Financial Investment
- Series A, May 13, 2022 — Anhong Capital
- Series A, Dec 7, 2021, $16M — Redhill Capital

## Investors

- Redhill Capital (https://capitalatlas.ai/funds/redhill-capital) — Series A
- Anhong Capital (https://capitalatlas.ai/funds/anhong-capital) — Series A
- ZJVC Venture Capital (https://capitalatlas.ai/funds/zjvc-venture-capital) — Series C
- Hengqin Financial Investment (https://capitalatlas.ai/funds/hengqin-financial-investment) — Series C